MYGNMyriad Genetics, Inc.

$454M

Q3 2018 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$202M+6.4% YoY

Gross Profit

$153M75.4% margin

Operating Income

$1M0.6% margin

Net Income

-$700,000-0.3% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$7M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$471M

Stockholders' Equity

$1.1B

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$202M	$190M	+6.4%
Gross Profit	$153M	$147M	+3.7%
Operating Income	$1M	$87M	-98.6%
Net Income	-$700,000	$81M	-100.9%

Revenue Segments

Diagnostics

$189M93%

All Other Segments

$13M7%

Geographic Segments

UNITED STATES

$192M95%

Non Us

$11M5%

MYGN Q3 2018 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena